These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 26223689)

  • 21. The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation.
    Loveman E; Jones J; Hartwell D; Bird A; Harris P; Welch K; Clegg A
    Health Technol Assess; 2010 Mar; 14(19):1-204. PubMed ID: 20356561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality?
    Aguiar PM; Lima TM; Storpirtis S
    J Clin Pharm Ther; 2016 Apr; 41(2):189-97. PubMed ID: 27009796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease.
    van Dussen L; Biegstraaten M; Hollak CE; Dijkgraaf MG
    Orphanet J Rare Dis; 2014 Apr; 9():51. PubMed ID: 24731506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
    Shepherd J; Cooper K; Harris P; Picot J; Rose M
    Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Issues surrounding orphan disease and orphan drug policies in Europe.
    Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
    Appl Health Econ Health Policy; 2010; 8(5):343-50. PubMed ID: 20804226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007.
    Orofino J; Soto J; Casado MA; Oyagüez I
    Appl Health Econ Health Policy; 2010; 8(5):301-15. PubMed ID: 20804223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
    Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A
    Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of orphan drugs on Latvian budget.
    Logviss K; Krievins D; Purvina S
    Orphanet J Rare Dis; 2016 May; 11(1):59. PubMed ID: 27169704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe.
    Schlander M; Adarkwah CC; Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):171-9. PubMed ID: 25312018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Shift of focus in the financing of Hungarian drugs. Reimbursement for orphan drugs for treating rare diseases: financing of enzyme replacement therapy in Hungary].
    Szegedi M; Molnár MJ; Boncz I; Kosztolányi G
    Orv Hetil; 2014 Nov; 155(44):1735-41. PubMed ID: 25344850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The actual status of drug prices and adjustment factors for drug price calculation: an analysis of ultra-orphan drug development in Japan.
    Kawakami A; Masamune K
    Orphanet J Rare Dis; 2022 Nov; 17(1):408. PubMed ID: 36348359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost effectiveness of fecal DNA screening for colorectal cancer: a systematic review and quality appraisal of the literature.
    Skally M; Hanly P; Sharp L
    Appl Health Econ Health Policy; 2013 Jun; 11(3):181-92. PubMed ID: 23549792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessing the economic challenges posed by orphan drugs.
    Drummond MF; Wilson DA; Kanavos P; Ubel P; Rovira J
    Int J Technol Assess Health Care; 2007; 23(1):36-42. PubMed ID: 17234015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical effectiveness and cost-effectiveness of second-eye cataract surgery: a systematic review and economic evaluation.
    Frampton G; Harris P; Cooper K; Lotery A; Shepherd J
    Health Technol Assess; 2014 Nov; 18(68):1-205, v-vi. PubMed ID: 25405576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
    Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J
    Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Orphan drugs: expensive yet necessary.
    Hyry HI; Roos JC; Cox TM
    QJM; 2015 Apr; 108(4):269-72. PubMed ID: 25434052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review of international coverage and pricing strategies for personalized medicine and orphan drugs.
    Degtiar I
    Health Policy; 2017 Dec; 121(12):1240-1248. PubMed ID: 29033060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Developing a patient-directed policy framework for managing orphan and ultra-orphan drugs throughout their lifecycle.
    Menon D; Stafinski T; Dunn A; Wong-Rieger D
    Patient; 2015 Feb; 8(1):103-17. PubMed ID: 25559762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mifamurtide for high-grade, resectable, nonmetastatic osteosarcoma following surgical resection: a cost-effectiveness analysis.
    Johal S; Ralston S; Knight C
    Value Health; 2013 Dec; 16(8):1123-32. PubMed ID: 24326165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.